| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0381 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 |
| filingDate |
2007-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5792ecad6b9425c1d38acc5493c780
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9dddbee0653464ffaaf80ff57e0184c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_317a5ef13d778b8534a2ab1dba6d3b50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dc0e095372cda978f9d854ac4b18619
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3cface34cc66392e9cacc29b83795ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa6146b55b10b11be2a42978bf1cdc1c |
| publicationDate |
2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008166338-A1 |
| titleOfInvention |
Il-21 as a regulator of immunoglobin production |
| abstract |
A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor. A mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function. A method is disclosed for altering a B cell activity. The method includes administering a therapeutically effective amount of an agent that interferes with the interaction of IL-21 with an IL-21 receptor, thereby altering the B cell activity. A method is also disclosed for of treating a subject with Job's disorder or atopic disease. A method is also disclosed for treating or preventing an allergic reaction in a subject. A method is also disclosed for treating a subject with an autoimmune or antibody mediated disorder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400134-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8455449-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11708392-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9959384-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11462297-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9951105-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10854312-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9133243-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9133244-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10808009-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9675672-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10227382-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10030058-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10030059-B2 |
| priorityDate |
2002-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |